Succinylcholine and nNMBAs with Coexisting Diseases and Conditions    body {font-family: 'Open Sans', sans-serif;}

### Succinylcholine and nNMBAs with Coexisting Diseases and Conditions

Nondepolarizing Neuromuscular Blocking Agents: (nNMBA)_Acetylcholine receptor_ (AChR)  
Succinylcholine (SCh)  
Neuromuscular junction (NMJ)  
Volume distribution (Vd)Recommend avoiding the administration of succinylcholine to all patients < 10 years old (especially males) for nonurgent procedures.**Age: Neonate** _In peds, SCh is only used for the emergency treatment of laryngospasm._ table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Require higher dose. 1.5-2.0 mg/kg |
| **Non-depolarizers:** | May have faster onset and longer duration. |
| **Notes:** | Despite the possible complications,  
SCh remains the gold standard for the  
treatment of pediatric laryngospasm.  
  
Possible pediatric complications  
of SCh result from:  
MH crises from undiagnosed MH.  
Severe hyperkalemia from undiagnosed neuromuscular diseases.  
Neonates have an increased sensitivity, but also have an increased Vd,  
which dilutes SCh.However,  
neonates sill requires a higher dose of SCh. |

**Age: Elderly** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Decrease dosage, prolonged onset. |
| **Non-depolarizers:** | Decrease dosage, prolonged onset and a longer duration. |
| **Notes:** | Prolonged onset, presumably due to deceased muscle blood flow and cardiac output associated with aging.  
Prolonged duration because organs of elimination (liver and kidneys) may not be working as well. |

**Amyotrophic Lateral Sclerosis (Lou Gehrig Disease)** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Contraindicated. May cause severe hyperkalemia and contractures. |
| **Non-depolarizers:** | Increased hypersensitivity |
| **Notes:** | Degeneration of upper and lower motor neurons. |

**Burns patients** (3 rd degree burns > 25% of total body surface) table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Contraindicated 24 hours after burn injury.  
May cause severe hyperkalemia. |
| **Non-depolarizers:** | Increased resistance, even in muscles not effected by burns. |
| **Notes:** | Onset of up-regulation (proliferation) of extrajunctional receptors occurs 24-48 hours after burn injury.  
Usually ends with healing but may last months to years.  
Despite healing time, SCh is usually avoided with all patients with a history of severe burn injury. |

  
  
**Cerebral Palsy (CP)** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Slight hypersensitivity |
| **Non-depolarizers:** | May show resistance or prolonged recovery. |
| **Notes:** | SCh is NOT contraindicated and may be desirable in patients with severe GERD. |

**Cirrhosis/Hepatic Disease** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | May need to increase dose.  
Possible increased duration. |
| **Non-depolarizers:** | Cisatracurium: Unchanged |
| **Notes:** | SCh: Possibly prolonged due to decreased synthesis of pseudocholinesterase.  
Elimination vecuronium and pancuronium may be prolonged due altered hepatic metabolism and biliary excretion.  
Rocuronium: Onset is longer due to increased Vd.  
Initial doses may need to be increased due to increased Vd. |

**Critically ill or immobilized > 3 days** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Caution: May cause severe hyperkalemia. |
| **Non-depolarizers:** | Safe, unless contraindicated coexisting disease is present requiring a lower dose. |
| **Notes:** | Immobilization is associated with the up-regulation of AChRs and spread of receptors beyond the NMJ.  
No apparent disruption of nerve function, however within 3-5 days of immobilization, the muscle fibers become atrophied, and the NMJ begins to show degenerative changes.  
Upregulation occurs will immobilization as early as 6-12 hours, but not critical enough to cause severe hyperkalemia with SCh until 3-5 days.  
There is up-regulation of AChRs and spread of receptors beyond the NMJ.  
Ask questions concerning immobility when called to the floors or ICU for intubation.  
Consider rocuronium and reversing with sugammadex. |

**Crush Injuries-Muscle trauma** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Caution: May cause severe hyperkalemia. |
| **Non-depolarizers:** | Little to no change |
| **Notes:** | Muscle trauma alters the muscle surface membrane much like denervation and thermal trauma. |

**Guillain-Barre Syndrome** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Contraindicated. May cause severe hyperkalemia. |
| **Non-depolarizers:** | Increased hypersensitivity |
| **Notes:** | Acute illness causing a rapidly progressive polyneuropathy with weakness or paralysis.  
Cause by an immune response resulting in an inflammatory demyelination starting at the level of the nerve roots.  
Can have mild muscle weakness to total quadriplegia, requiring mechanical ventilation.  
Most patients completely recover or are left with minor sequela.  
20% remain disabled. |

**Hemiplegia** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Caution: May cause severe hyperkalemia. |
| **Non-depolarizers:** | Increased resistance on affected side. |

  
  
**Hepatic/Cirrhosis, Liver Disease** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Not contraindicated but may prolong effects  
due to a decreased plasma cholinesterase level. |
| **Non-depolarizers:** | Cisatracurium: Drug of choice with compromised liver function. |
| **Notes:** | The elimination of Cisatracurium is independent of liver function. |

**Hyperkalemic Periodic Paralysis** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Contraindicated.  
Can increase K+ enough to precipitate  
Hyperkalemic Periodic Paralysis. |
| **Non-depolarizers:** | Normal to hypersensitivity |
| **Notes:** | Hyperkalemia may cause intermittent skeletal muscle weakness that spares the respiratory muscles.  
Not a neuromuscular problem, but a problem at the muscle membrane itself.  
Believed to be a Na channel pathology.  
Precipitated by exercise.  
  
Avoid hypothermia, K+ infusions or anything that may cause increases in K+ levels. |

**Hypokalemic Periodic Paralysis** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | OK to use |
| **Non-depolarizers:** | OK to use |
| **Notes:** | Hypokalemia may cause intermittent skeletal muscle weakness that spares the respiratory muscles.  
  
Avoid all causes of hypokalemia: Stress, hypothermia, carbohydrate loads,  
IV containing glucose solutions, beta agonist (catecholamines). |

**Increased ICP** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Minor increase in ICP |
| **Non-depolarizers:** | Little change |
| **Notes:** | Inadequate anesthesia during a direct laryngoscopy or increased PaCO2  
or hypoxia with a difficult airway will result with a much higher ICP than a dose of ScH. |

**Increased Intraocular Pressure (IOP)** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Not absolutely contraindicated for open eye injury. |
| **Non-depolarizers:** | No change |
| **Notes:** | SCh causes only a slight temporary increase in IOP and OK for open eye procedures when indicated.  
IOP increases in 1 minute and within 6 minutes, IOP may increase to 9 mmHg.  
There is little evidence that SCh increases chance of blindness or extrusion of eye content.  
  
Rocuronium is still very popular when prolonged muscle relaxant is required. |

**Malignant Hyperthermia** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Contraindicated |
| **Non-depolarizers:** | No change in effect |
| **Notes:** | SCh is a trigger to MH |

**Multiple Sclerosis** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Caution: May cause severe hyperkalemia. |
| **Non-depolarizers:** | Normal to sensitive |
| **Notes:** | Progressive neurologic denervating disease |

**Muscular Denervation** (peripheral nerve injury) table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Relatively contraindicated: May cause severe hyperkalemia and contracture. |
| **Non-depolarizers:** | Normal response or increase in resistance |
| **Notes:** | SCh produces sustained muscle contractions lasting several minutes in patients with a denervated muscle. |

  
  
**Muscular Dystrophy** (Duchenne) and other dystrophinopathies table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Contraindicated. May cause "Anesthesia Induced Rhabdomyolysis" (AIR) and/or severe hyperkalemia. |
| **Non-depolarizers:** | Unpredictable  
Reports of normal and sporadic cases of increased sensitivity. |
| **Notes:** | Dystrophinopathy and rhabdomyolysis  
Dystrophinopathies can develop "AIR" and MH-like symptoms after being exposed to MH trigger agents (ScH and inhalation agents).  
These patients DO NOT have ryanodine receptor abnormalities and probably are no more susceptible to MH than the rest of the population. |

**Myasthenic Gravis (MG)** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Increased resistance, but safe to administer. |
| **Non-depolarizers:** | Hypersensitivity |
| **Notes:** | Autoimmune. Autoantibodies attack postsynaptic acetylcholine receptors.  
These patients get very weak with exercise.  
Hypersensitive to **Non-depolarizers:** Because of the decreased amount of postjunctional receptors. Rocuronium has to compete for neuromuscular blockade.  
  
Treatment: Pyridostigmine or neostigmine which are both anticholinesterase drugs and increase the level of Ach to potentially improve symptoms.  
However, these meds also decrease levels of plasma cholinesterase, which may offset the resistance of SCh.  
Despite the being on anticholinesterase drugs, MG patients are still considered hypersensitive to nondepolarizing muscle relaxant agents.  
MG is a postsynaptic issue, Myasthenic Syndrome is a presynaptic issue. |

**Myasthenic Syndrome** (Eaton Lambert also Lambert Eaton) table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Hypersensitivity |
| **Non-depolarizers:** | Hypersensitivity |
| **Notes:** | Autoantibodies attack and damage the Ca channels which results in inadequate presynaptic release of acetylcholine.  
Muscle weakness improves with exercise. Less respiratory involvement.  
Associated with lung cancer.  
MG is a postsynaptic issue, Myasthenic Syndrome is a presynaptic issue. |

**Myotonias:** Myotonic Dystrophy and Paramyotonia Congenital table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Relatively contraindicated.  
May cause generalized muscle contractions. |
| **Non-depolarizers:** | Normal or hypersensitive |
| **Notes:** | Sustained, dose related generalized contracture and muscles making ventilation difficult.  
Pathophysiology is not the neuromuscular junction, it is the muscle itself.  
Also avoid etomidate and neostigmine.  
Regional anesthesia, muscle relaxants and dantrolene DOES NOT reverse a myotonia event.  
 |

**Obesity** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Increase resistance  
(Some providers dose 1.5mg/kg of ideal body weight) |
| **Non-depolarizers:** | No change |

**Plasma Pseudocholinesterase Deficiency** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Contraindicated. Will result in a phase II depolarizing block |
| **Non-depolarizers:** | No issues |
| **Notes:** | **Heterozygous** may result in phase II depolarizing block up to 30 minutes.  
**Homozygous** may result in phase II depolarizing block > 3 hours. |

  
  
**Renal Failure** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Not contraindicated.  
Patient should have recent dialysis and normal K+ levels.  
May be prolonged. |
| **Non-depolarizers:** | **Cisatracurium:** Safest alternative |
| **Notes:** | ShC will usually increase plasma K+ level by 0.5meq/L  
Patient who has not recently been dialyzed with a K+ of 6.0 or 6.5, SC may be enough to cause cardiac problems (hyperkalemic ventricular fibrillation).  
**Vecuronium:** Prolonged  
**Rocuronium:** Relatively unchanged  
Pancuronium is prolonged the longest.  
There is reduced plasma cholinesterase activity with renal failure. |

**Severe Sepsis/Chronic Infection:** _Clostridium_ Tetanus (lockjaw) and _Clostridium_ Botulismand other exotoxin infections. table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Caution: May cause severe hyperkalemia |
| **Non-depolarizers:** | May increases resistance |
| **Notes:** | Clostridium botulinum and tetani, causing botulism and tetanus, effects the neuromuscular junction. Lockjaw is now called trismus.  
  
Released exotoxins cause a decreased release of acetylcholine resulting in paralysis of certain muscles. This causes an up regulation of AChRs.  
  
Hyperkalemia has also been reported in intraabdominal sepsis >5 days old. |

  
  
**Spinal Cord Injury (SCI) > 24 hours** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  |   |
| --- | --- |
| **Depolarizers (SCh):** | Caution post 24 hours after injury.  
May cause severe hyperkalemia |
| **Non-depolarizers:** | Little to no change. |
| **Notes:** | ShC should be avoided between 24 hours and 9 months following SCI due to the risk of succinylcholine induced hyperkalemia caused by denervation hypersensitivity.  
Despite the literature, most anesthesia providers permanently avoid succinylcholine with these patients, rather than just for 9 months after SCI. |

  
  
FDA, Anesthetic and Life Support Drugs Advisory Committee and the Pilot Drug review team, along with the four manufacturers of succinylcholine, have recently stated that succinylcholine is contraindicated for routine use in children and adolescents except for emergency tracheal intubation or in instances where immediate securing of the airway is necessary.denervation injuries or disorders.  
  
**Other reasons NOT to use SCh  
**Hypersensitivity to succinylcholine or parabens.  
  
**Use SCh cautiously in patients with:**  
History of anaphylaxis to other neuromuscular blockers  
Familial history of malignant hyperthermia  
History of pulmonary disease, renal or liver impairment  
Glaucoma  
Electrolyte disturbances  
Receiving digoxin  
**OB:** Has been used in pregnant women undergoing cesarean section.  
  

Succinylcholine-induced Hyperkalemia in Acquired Pathologic States: Etiologic Factors and Molecular Mechanisms  
Anesthesiology 1 2006, Vol.104, 158-169.  
J A. Jeevendra Martyn, M.D., F.R.C.A., F.C.C.M.; Martina Richtsfeld, M.D.  
Neuromuscular Blockers and Coexisting Diseases  
University of Kentucky Department of Anesthesiology (accessed 02/2020)  
Randall Schell M.D.  
https://www.youtube.com/watch?v=8aeM2gTBVPE&t=115s  
  
Keyword Review 2019 | Pharmacology 1 of 3  
University of Kentucky Department of Anesthesiology (accessed 02/2020)Randall Schell M.D.  
https://www.youtube.com/watch?v=qsDIFVpv2Po  
  
Succinylcholine  
Anesthesia Central (accessed 02/2020)  
https://anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/51711/all/succinylcholine  
  
Succinylcholine-induced hyperkalemia in neuromuscular disease.  
JAMA. 1970;213:1867–1871.  
Cooperman LH.  
  
Handbook of Anesthesia, 5th Ed. 2014 ; pp. 698-99  
J. Nagelhout and K. Plaus  
  
Handbook of Anesthesia, 6th Ed. 2017 ; pp. 150  
John J. Nagelhout CRNA PhD FAAN and Sass Elisha EdD CRNA FAAN  
  
Anesthetic considerations in acute spinal cord trauma  
International Journal of Critical Illness & Injury Science  
2011 Jan-Jun; 1(1): 36–43.  
  
Neuromuscular Diseases: Succinylcholine Hyperkalemia  
Open Anesthesia (accessed 02/2020)  
https://www.openanesthesia.org/neuromuscular\_disease\_succinylcholine\_hyperkalemia/  
  
Cardiac Arrest after Succinylcholine: Mortality Greater with Rhabdomyolysis Than Receptor Upregulation  
“Anesthesiology 3 2001, Vol.94, 523-529.  
Gerald A. Gronert, M.D.  
  
Perioperative Management for patients with chronic spinal injury  
British Journal of Anesthesia Education 15 (3): 123–130 (2015)  
Anna Petsas BSc MBBS FRCA and Jeremy Drake MBBS FRCA  
  
In My Opinion: A Debate: Is Succinylcholine Safe for Children?  
NEWSLETTER: The Official Journal Of The Patient Safety Foundation; Vol. 9, No. 1, Spring 1994.  
Susan K. Woelfel, M.D.; Robert C. Morell, M.D.; Jeffrey M. Berman, M.D.  
  
The effect of succinylcholine on denervated skeletal muscle  
Journal of a Hans Surgery; 1981 Jan;6(1):40-2.  
Doyle JR, Semenza J, Gilling B.  
Crush-Related Injury after Disasters  
The New England Journal of Medicine; 2006; 354:2511-2512  
  
Perioperative Drug Therapy in Elderly Patients  
Anesthesiology 5 2009, Vol.110, 1176-1181.  
Richard Rivera, M.D.; Joseph F. Antognini, M.D.  
  
Succinylcholine  
Anesthesia Central  
Davis Drug Guide (accessed 02/2020)  
https://anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/51711/all/succinylcholine?q=succinylcholine#4